Novel platinum pyridinehydroxamic acid complexes: Synthesis, characterisation, X-ray crystallographic study and nitric oxide related properties

[1]  B. Bonavida,et al.  Therapeutic potential of nitric oxide in cancer. , 2006, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[2]  Mika Kettunen,et al.  Platinum group antitumor chemistry: design and development of new anticancer drugs complementary to cisplatin. , 2006, Current medicinal chemistry.

[3]  J. Reedijk,et al.  Targeting platinum anti-tumour drugs: Overview of strategies employed to reduce systemic toxicity , 2005 .

[4]  M. Jakupec,et al.  Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. , 2005, Current medicinal chemistry.

[5]  P. Bottoni,et al.  Nitric oxide donor drugs: an update on pathophysiology and therapeutic potential , 2005, Expert opinion on investigational drugs.

[6]  G. Thatcher.  An introduction to NO-related therapeutic agents. , 2005, Current topics in medicinal chemistry.

[7]  F. M. Dolgushin,et al.  Synthesis, characterisation and speciation studies of heterobimetallic pyridinehydroxamate-bridged Pt(II)/M(II) complexes (M = Cu, Ni, Zn). Crystal structure of a novel heterobimetallic 3-pyridinehydroxamate-bridged Pt(II)/Cu(II) wave-like coordination polymer. , 2005, Dalton transactions.

[8]  H. den Dulk,et al.  Synthesis, characterization, in vitro antitumor activity, DNA-binding properties and electronic structure (DFT) of the new complex cis-(Cl,Cl)[RuIICl2(NO+)(terpy)]Cl. , 2005, Dalton transactions.

[9]  A. Bergamo,et al.  Ruthenium antimetastatic agents. , 2004, Current topics in medicinal chemistry.

[10]  S. Fricker,et al.  Ruthenium as an effective nitric oxide scavenger. , 2004, Current topics in medicinal chemistry.

[11]  E. Zangrando,et al.  A novel ruthenium nitrosyl complex which also contains a free NO-donor moiety , 2004 .

[12]  K. Nolan,et al.  Hydroxamic Acids − An Intriguing Family of Enzyme Inhibitors and Biomedical Ligands , 2004 .

[13]  H. Tanke,et al.  Dinuclear platinum complexes with N,N′-bis(aminoalkyl)-1,4-diaminoanthraquinones as linking ligands. Part I. Synthesis, cytotoxicity, and cellular studies in A2780 human ovarian carcinoma cells , 2004, JBIC Journal of Biological Inorganic Chemistry.

[14]  N. Farrell.  Polynuclear platinum drugs. , 2004, Metal ions in biological systems.

[15]  M. Hall,et al.  Platinum(IV) anticancer complexes. , 2004, Metal ions in biological systems.

[16]  G. Natile,et al.  Antitumor active trans-platinum compounds. , 2004, Metal ions in biological systems.

[17]  C. Napoli,et al.  Nitric oxide-releasing drugs. , 2003, Annual review of pharmacology and toxicology.

[18]  Jaw‐Jou Kang,et al.  Induction of vasorelaxation through activation of nitric oxide synthase in endothelial cells by brazilin. , 2003, European journal of pharmacology.

[19]  S. Donnini,et al.  Role of nitric oxide in the modulation of angiogenesis. , 2003, Current pharmaceutical design.

[20]  A. Korolev,et al.  Nitric oxide donor increases the efficiency of cytostatic therapy and retards the development of drug resistance. , 2003, Nitric oxide : biology and chemistry.

[21]  Weiming Xu,et al.  The role of nitric oxide in cancer , 2002, Cell Research.

[22]  Christian Bogdan,et al.  Nitric oxide and the immune response , 2001, Nature Immunology.

[23]  T. Murphy,et al.  Hydroxamic acids are nitric oxide donors. Facile formation of ruthenium(II)-nitrosyls and NO-mediated activation of guanylate cyclase by hydroxamic acids , 2000 .

[24]  C. Szabó,et al.  DNA damage induced by peroxynitrite: subsequent biological effects. , 1997, Nitric oxide : biology and chemistry.

[25]  T. Pakkanen,et al.  Conformational behaviour of hydroxamic acids: ab initio and structural studies , 1996 .

[26]  John D. Roberts,et al.  Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action. , 1991, Cancer research.

[27]  B. Lippert,et al.  An alternative HPLC method for analysing mixtures of isomeric platinum(II) diamine compounds , 1987 .

[28]  A. Diamantis,et al.  Preparation and structure of ethylenediaminetetraacetate complexes of ruthenium(II) with dinitrogen, carbon monoxide, and other .pi.-acceptor ligands , 1981 .

[29]  G. Wampler,et al.  Synthesis of hydroxy- and amino-substituted benzohydroxamic acids: inhibition of ribonucleotide reductase and antitumor activity. , 1979, Journal of medicinal chemistry.

[30]  K. Nakamoto.  Infrared and Raman Spectra of Inorganic and Coordination Compounds , 1978 .